On September 14, Novartis AG rose 3.19% in regular trading, trading at $139.49/share, with turnover of approximately $72.85 million. The rebound was driven by a convergence of positive catalysts following a steep selloff the prior week.
On the news front, top-20 shareholder Artisan Partners publicly called for a board overhaul, with Managing Director David Samra urging stronger oversight of acquisitions. Samra specifically questioned the $12 billion Avidity deal and the earlier MorphoSys acquisition, which had already been written down. The market interpreted the activist pressure as a constructive signal for improved corporate governance. Separately, HSBC upgraded Novartis to Hold with a CHF110 price target, while RBC Capital Markets initiated coverage at Sector Perform with a CHF120 target.
The rally comes after Novartis shares plunged over 13% in the prior week following three consecutive clinical setbacks, including the failure of pelacarsen in its Phase III cardiovascular outcomes trial, the del-desiran Phase III miss in myotonic dystrophy type 1, and the suspension of eight CAR-T therapy trials due to patient deaths. The current move reflects a technical rebound amplified by multiple positive developments.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments